News - Naveris

Filter

All Press Release

Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance

Naveris Announces Expanded Commercial Payor Coverage for NavDx Test from Blue Shield of California

Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting

Naveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting

New Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings

Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting

Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer

Naveris Awarded ADLT Status by CMS for the NavDx® Test

Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024

Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to Advance HPV-Driven Cancer Diagnosis and Treatment

Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024

Naveris Announces Commercial Payor Coverage for NavDx® Test from Highmark, Inc.